Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

DARE-19, 2021 NCT04350593

dapagliflozin (n=-9) vs. placebo (n=-9)

randomized controlled trial   risk of bias NA

Studied treatment

dapagliflozin for 30 days

Control treatment

placebo

Patients

COVID 19 hospitalized

Method

Remark

trial did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality according to a AZ press release

Abuhasira, 2021 NCT04371978

DPP-4 inhibitor (n=32) vs. standard of care (n=32)

randomized controlled trial   some concerns about risk of bias

Studied treatment

linagliptine
5 mg/dfrom randomization to hospital discharge

Control treatment

standard of care
diabetes treatment included holding oral drugs and initiating insulin therapy according to a basal bolus protocol. The goal of therapy was to keep blood glucose levels in the range of 140–180 mg/dl.

Patients

COVID-19 severe or critically

Method

open-label

3 centers, Israel

Clinical change is defined as 2 points reduction in the 9-point World Health Organization (WHO) Ordinal Scale for Clinical Improvement

Remark

The trial was prematurely terminated due to the control of the COVID-19 outbreak in Israel.